4 Quotes by Eric Bernhardt

It is a good marketing tool that the FDA has approved it, so I am quite sure they will make some inroads in the U.S. That is for sure.

There may be one or two dollars more in the bid but I think the price does reflect the business. If they had a fantastic product in late-stage testing, you'd offer more but you don't make a spectacular bid for a company that's not spectacular.

It's still the beginning, and the beginning is when you have to be tough.

The jewels are the vaccines business and blood testing. There's nothing about Chiron that makes you say 'wow, we need to buy this for the pipeline.' The portfolio is rather lackluster compared to other biotechnology companies.